Turning Rare into Routine: The Orphan Drug Revolution

Rare diseases affect over 350 million people globally, half of whom are children. Despite this, more than 90% of these conditions still lack approved treatments, highlighting a significant unmet need and a substantial opportunity.

Orphan drugs, developed specifically for rare diseases, have demonstrated remarkable growth over the past decade, surpassing non-orphan drug sales and recently leading FDA approvals. While these drugs offer substantial rewards, their success depends on complex, high-stakes launches, making an optimal launch strategy essential.

See our previous reports about Rare Diseases

Download the full report to learn more and comment below to receive our comprehensive report, which includes:

• Detailed analysis and case studies
• Expert insights on maximizing launch potential